Comparative Pharmacology
Head-to-head clinical analysis: GENTAFAIR versus NEOMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAFAIR versus NEOMYCIN SULFATE.
GENTAFAIR vs NEOMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and causing misreading of mRNA, leading to cell death.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing bacterial cell death by disrupting the cytoplasmic membrane.
Gentamicin 3-5 mg/kg IV or IM once daily for serious infections; alternatively, 1.5-2 mg/kg IV or IM every 8 hours.
1-2 g orally 4 times daily (8-16 g/day) for hepatic encephalopathy or intraluminal infection; 0.5-1 g orally 4 times daily for preoperative bowel preparation.
None Documented
None Documented
2-3 hours (normal renal function); may extend to 24-48 hours in severe renal impairment, necessitating dose adjustment.
2-3 hours (normal renal function); prolonged to 20-60 hours in anuria
Renal: over 90% unchanged via glomerular filtration; minor biliary (<1%).
Renal (glomerular filtration) >90% unchanged; small amount biliary/fecal (<3%)
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic